# Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

> **NCT01596751** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hope Rugo, MD** · enrollment: 67 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** PLX3397
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT01596751
- **Lead sponsor:** Hope Rugo, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-12
- **Primary completion:** 2017-07-05
- **Final completion:** 2019-07-05
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2020-07-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01596751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01596751, "Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01596751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*